Arcus Biosciences (NYSE:RCUS) First Quarter 2025 Results

Key Financial Results

• Revenue: US$28.0m (down 81% from 1Q 2024).
• Net loss: US$112.0m (loss widened by US$108.0m from 1Q 2024).
• US$1.14 loss per share (further deteriorated from US$0.046 loss in 1Q 2024).

Our free stock report includes 2 warning signs investors should be aware of before investing in Arcus Biosciences. Read for free now.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Arcus Biosciences Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 27%. Earnings per share (EPS) also missed analyst estimates by 11%.

Looking ahead, revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

The company's shares are down 8.5% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Arcus Biosciences, and understanding these should be part of your investment process.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.